Table 2.
Early PET/CT result | EOT responder (n=9)† | EOT non-responder (n=7)† | P – value | |
---|---|---|---|---|
D4 Visual | 24 | |||
Response (CR + PR) | 14 (58) | 4 (50) | 4 (57) | 1.0 |
Non-response (SD + PD) | 10 (42) | 4 (50) | 3 (43) | |
D4 ΔSUVmax | 23 | |||
>50% | 10 (43) | 5 (71) | 2 (29) | 0.29 |
≤50% | 13 (57) | 2 (29) | 5 (71) | |
D4 ΔSUVmax, median (range) | 45 (−76 – 89)* | 57 | 37 | 0.37 |
D21 Visual | 22 | |||
Response (CR + PR) | 7 (32) | 3 (38) | 2 (33) | 1.0 |
Non-response (SD + PD) | 15 (68) | 5 (62) | 4 (67) | |
D21 ΔSUVmax | 21 | |||
>50% | 5 (24) | 3 (43) | 1 (17) | 0.56 |
≤50% | 16 (76) | 4 (57) | 5 (83) | |
D21 ΔSUVmax, median (range) | 26 (−140 – 89)* | 42 | 29 | 0.94 |
Response on D4 & D21 | 23 | |||
Y | 6 (26) | 3 (38) | 1 (17) | 0.58 |
N | 17 (74) | 5 (62) | 5 (83) | |
ΔSUVmax >50% on D4 & D21 | 22 | |||
Y | 4 (18) | 3 (43) | 0 (0) | 0.19 |
N | 18 (82) | 4 (57) | 6 (100) |
positive number represents decrease in SUVmax
Excludes patients who did have early PET/CTs performed but were missing EOT PET/CT evaluation
PET/CT, positron emission tomography/computed tomography; EOT, end-of-treatment; D4, day 4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; SUVmax, maximum standardized uptake value; D21, day 21